Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method of treating an inflammatory disorder in a subject comprising:

administering to a subject an effective amount of a compound selected from the group consisting of (1) a compound having the formula:



,

wherein:

R^1 is selected from the group consisting of:

H;

substituted or unsubstituted phenyl, and

substituted or unsubstituted naphthalene;

R^2 is selected from the group consisting of:

H;

C_1-C_4 alkyl;

substituted or unsubstituted phenyl;

NH_2;

$CH_2COOCH_2CH_3$, and

$COOCH_2CH_3$;

(2) a compound having the formula:



wherein:

R^1 is selected from the group consisting of:

H and

C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

C_1-C_4 alkyl;

substituted or unsubstituted phenyl;

substituted or unsubstituted furan;

substituted or unsubstituted cyclohexyl;

substituted or unsubstituted naphthalene;

substituted or unsubstituted indol;

substituted or unsubstituted pyridine, and

substituted or unsubstituted thiophene;

(3) a compound having the formula:



wherein:

R^1 is selected from the group consisting of:

H and

C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

substituted or unsubstituted pyridine and

substituted or unsubstituted phenyl;

(4) a compound having the formula:



,

wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl;

R^3 is substituted or unsubstituted quinoline with or without a linking group;

and (5) a compound having the formula:



,

wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl;

R^3 is substituted or unsubstituted benzoylhydrazino;

thereby treating the inflammatory disorder in the subject.

2. (Original) The method according to claim 1, wherein the compound has the formula:



wherein:

R^1 is selected from the group consisting of:

H;

substituted or unsubstituted phenyl, and

substituted or unsubstituted naphthalene;

R^2 is selected from the group consisting of:

H;

C_1-C_4 alkyl;

substituted or unsubstituted phenyl,

NH_2;

$CH_2COOCH_2CH_3$, and

$COOCH_2CH_3$.

3. (Original) The method according to claim 2, wherein the compound has the formula:



4. (Original) The method according to claim 1, wherein the compound has the formula:



wherein:

R^1 is selected from the group consisting of:

H and C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

C_1-C_4 alkyl;

substituted or unsubstituted phenyl;

substituted or unsubstituted furan;

substituted or unsubstituted cyclohexyl;

substituted or unsubstituted naphthalene;

substituted or unsubstituted indol;

substituted or unsubstituted pyridine, and

substituted or unsubstituted thiophene.

5. (Original) The method according to claim 4, wherein the compound has the formula:



6. (Original) The method according to claim 1, wherein the compound has the formula:



wherein:

R^1 is selected from the group consisting of:

H and

C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

substituted or unsubstituted pyridine and

substituted or unsubstituted phenyl.

7. (Original) The method according to claim 6, wherein the compound has the formula:



8. (Original) The method according to claim 6, wherein the compound has the formula:



9. (Original) The method according to claim 1, wherein the compound has the formula:



wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl; and

R^3 is substituted or unsubstituted quinoline with or without a linking group.

10. (Currently Amended) The method according to claim 9, wherein the compound has the formula:



11. (Original) The method according to claim 1, wherein the compound has the formula:



wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl; and

R^3 is substituted or unsubstituted benzoylhydrazino.

12. (Original) The method according to claim 11, wherein the compound has the formula:



13. (Original) The method according to claim 11, wherein the compound has the formula:



14. (Original) The method according to claim 11, wherein the compound has the formula:



15. (Original) The method according to claim 11, wherein the compound has the formula:



16. (Original) The method according to claim 11, wherein the compound has the formula:



17. (Original) The method according to claim 11, wherein the compound has the formula:



18. (Original) The method according to claim 11, wherein the compound has the formula:



19. (Original) The method according to claim 1, wherein the compound is administered as part of a composition further comprising a pharmaceutically-acceptable carrier.

20. (Original) The method according to claim 1, wherein said administrating is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intravesical instillation, by intracavitary, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membrane.

21. (Original) The method according to claim 1, wherein the inflammatory disorder is selected from the group consisting of ischemia-reperfusion injury, occlusive and embolic stroke, myocardial infarction, type I diabetes mellitus, asthma, chronic obstructive pulmonary disease, gout, pre-term labor, sarcoidosis, ulcerative colitis, rheumatoid arthritis, osteoarthritis, xenograft rejection, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, pemphigus, chronic obstructive pulmonary disease, systemic lupus erythematosus, atopic dermatitis, vasculitides, Wegener's Syndrome, Goodpasture's Syndrome, giant cell arteritis, polyarteritis nodosa, multiple sclerosis, Alzheimer's Disease, Crohn's Disease regional enteritis, sepsis syndrome, post-streptococcal glomerulonephritis, hepatitis C, *Neisserial* or *Pneumococcal* meningitis, *Helicobacter pylori* gastritis, influenza virus pneumonia, tuberculosis, tuberculoid leprosy, filariasis, cystic fibrosis, bacterial dysentery, Chagas Disease (*Trypanosoma cruzi*), schistosomiasis, idiopathic pulmonary fibrosis, hepatic cirrhosis, radiation-induced pulmonary fibrosis, chronic allograft rejection, and bleomycin-induced pulmonary fibrosis.

22. (Original) The method according to claim 1, wherein the subject is a mammal.

23. (Original) The method according to claim 22, wherein the mammal is a human.

24. (Currently amended) A method of inhibiting respiratory burst in adherent neutrophils without inhibiting neutrophil degranulation in or bacterial killing by neutrophils, said method comprising:

contacting adherent neutrophils with an effective amount of a chemical compound selected from the group consisting of (1) a compound having the formula:



wherein:

R^1 is selected from the group consisting of:

H;

substituted or unsubstituted phenyl, and

substituted or unsubstituted naphthalene;

R^2 is selected from the group consisting of:

H;

C_1-C_4 alkyl;;

substituted or unsubstituted phenyl;

NH_2;

$CH_2COOCH_2CH_3$, and

$COOCH_2CH_3$;

(2) a compound having the formula:



wherein:

R^1 is selected from the group consisting of:

H and

C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

C_1-C_4 alkyl;

substituted or unsubstituted phenyl;

substituted or unsubstituted furan;

substituted or unsubstituted cyclohexyl;

substituted or unsubstituted naphthalene;

substituted or unsubstituted indol;

substituted or unsubstituted pyridine; and

substituted or unsubstituted thiophene;

(3) a compound having the formula:



wherein:

R^1 is selected from the group consisting of:

H and C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

substituted or unsubstituted pyridine; and

substituted or unsubstituted phenyl;

(4) a compound having the formula:



wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl;

R^3 is substituted or unsubstituted quinoline with or without a linking group;

and (5) a compound having the formula:



wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl; and

R^3 is substituted or unsubstituted benzoylhydrazino.

25. (Original) The method according to claim 24, wherein the compound has the formula:



wherein:

R^1 is selected from the group consisting of:

H;

substituted or unsubstituted phenyl, and

substituted or unsubstituted naphthalene;

R^2 is selected from the group consisting of:

H;

C_1-C_4 alkyl

substituted or unsubstituted phenyl,

NH_2;

$CH_2COOCH_2CH_3$; and

$COOCH_2CH_3$.

26. (Original) The method according to claim 25, wherein the compound has the formula:



27. (Original) The method according to claim 24, wherein the compound has the formula:



wherein:

R^1 is selected from the group consisting of:

H and

C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

C_1-C_4 alkyl;

substituted or unsubstituted phenyl;

substituted or unsubstituted furan;

substituted or unsubstituted cyclohexyl;

substituted or unsubstituted naphthalene;

substituted or unsubstituted indol;

substituted or unsubstituted pyridine, and

substituted or unsubstituted thiophene.

28. (Original) The method according to claim 27, wherein the compound has the formula:



29. (Original) The method according to claim 24, wherein the compound has the formula:



wherein:

R^1 is selected from the group consisting of:

H and

C_1-C_4 alkyl;

R^2 is selected from the group consisting of:

substituted or unsubstituted pyridine and

substituted or unsubstituted phenyl.

30. (Original) The method according to claim 29, wherein the compound has the formula:



31. (Original) The method according to claim 29, wherein the compound has the formula:



32. (Original) The method according to claim 24, wherein the compound has the formula:



wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl; and

R^3 is substituted or unsubstituted quinoline with or without a linking group.

33. (Currently Amended) The method according to claim 32, wherein the compound has the formula:





34. (Original) The method according to claim 24, wherein the compound has the formula:



wherein:

R^1 is substituted or unsubstituted phenyl;

R^2 is C_1-C_4 alkyl; and

R^3 is substituted or unsubstituted benzoylhydrazino.

35. (Original) The method according to claim 34, wherein the compound has the formula:



36. (Original) The method according to claim 34, wherein the compound has the formula:



37. (Original) The method according to claim 34, wherein the compound has the formula:



38. (Original) The method according to claim 34, wherein the compound has the formula:



39. (Original) The method according to claim 34, wherein the compound has the formula:



40. (Original) The method according to claim 34, wherein the compound has the formula:



41. (Original) The method according to claim 34, wherein the compound has the formula:



42. (Original) The method according to claim 24, wherein said contacting neutrophils is carried out *in vitro*.

43. (Original) The method according to claim 24, wherein said contacting neutrophils is carried out *in vivo*.

44. (Original) The method according to claim 24, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by an agent selected from the group consisting of a chemokine, a cytokine, bacteria, and a bacterial factor.

45. (Original) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a chemokine selected from the group consisting of macrophage inflammatory protein-1 (MIP-1), interleukin-8 (IL-8), and chemoattractant complement component C5a.

46. (Original) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a cytokine selected from the group consisting of tumor necrosis factor (TNF), lymphotoxin, granulocyte-specific colony stimulating factor (G-CSF), and granulocyte/macrophage-specific colony stimulating factor (GM-CSF).

47. (Original) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by bacteria selected from the group consisting of whole bacteria, bacterial cell wall components, and secreted or shed bacterial products.

48. (Original) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a bacterial factor that is a soluble bacterial complement protein.